BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, March 29, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Sep. 17, 2009
View Archived Issues
Neurocrine Snares $75M CEFF to Hunt for Products to License
Neurocrine Biosciences Inc. has secured a commitment from Kingsbridge Capital Ltd. to purchase shares in the company through a warrant-free equity financing that would provide up to $75 million over three years. (BioWorld Today)
Read More
Pervasis Tackling PAD with $17M Round; Seeks Vascugel Partner
Read More
Commercialization Conundrum: Partnering vs. Building a FIPCO
Read More
Despite Concerns, Panel Favors Auxilium's Xiaflex in Dupuytren's
Read More
IPOs on Parade: Anthera Seeks $70M to Fund Cardio Studies
Read More
CMS Bundling Rule: Bad News for Amgen Now, Genzyme Later
Read More
Other News To Note
Read More
Clinic Roundup
Read More